ConductScience.org, home

Paper40539389

A Nano-Electro-Platform Enabling Evolutionary Screening and Remodeling of Tumor Cells for Metastasis Inhibition.

Liu F and 20 others. Adv Sci (Weinh), 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. A Nano-Electro-Platform Enabling Evolutionary Screening and Remodeling of Tumor Cells for Metastasis Inhibition. Papers, record 40539389. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40539389

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Nano-Electro-Platform Enabling Evolutionary Screening and Remodeling of Tumor Cells for Metastasis Inhibition.
PubMed
Journal
Adv Sci (Weinh)
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2025-09-19
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu FFeng
2Sun HHong
3Liu BBing
4Zhang JJing
5Wu CChengbao
6Yan SShi
7Tai CChengzheng
8Tong YYihang
9Su RRongtai
10Xiang XXiaowei
11Wu HHan
12Yao FFuqi
13Yang KKuan
14Yin DDedong
15Wang YYuqiong
16Xiao AAo
17Cheng LLong
18Chen XXi
19Wu NNan
20Dong ZZaizai

Source PubMed

See all 21 authorsDownload CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Neoplasm MetastasisMajor topic
Extracellular VesiclesMajor topic
Lung NeoplasmsMajor topic
Humans
Animals
Mice
Cell Line, Tumor

Source PubMed

Download CSV of topics

Grants12

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
2023YFC2415900National Key Technologies Research and Development ProgramPubMed
2022YFB3205601National Key Technologies Research and Development ProgramPubMed
2022YFB3205602National Key Technologies Research and Development ProgramPubMed
22304006National Natural Science Foundation of ChinaPubMed
62471021National Natural Science Foundation of ChinaPubMed
T24B2006National Natural Science Foundation of ChinaPubMed
82303583National Natural Science Foundation of ChinaPubMed
82373082National Natural Science Foundation of ChinaPubMed
T2425021National Science Fund for Distinguished Young ScholarsPubMed
JKF-20240574Fundamental Research Funds for the Central UniversitiesPubMed
2022-11Science Foundation of Peking University Cancer HospitalPubMed
2024-1-1023Capital's funds for health improvement and researchPubMed

Source PubMed

Download CSV of grants

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123325802Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice.Sci Transl Med2013https://conductscience.org/library/papers/23325802PubMed
233899000Emerging strategies for treating metastasis.Nat Cancer2021https://conductscience.org/library/papers/33899000PubMed
325850553Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.Nat Rev Clin Oncol2015https://conductscience.org/library/papers/25850553PubMed
432650041Liposomes: Advancements and innovation in the manufacturing process.Adv Drug Deliv Rev2020https://conductscience.org/library/papers/32650041PubMed
537429944Roles of macrophages in tumor development: a spatiotemporal perspective.Cell Mol Immunol2023https://conductscience.org/library/papers/37429944PubMed
636635419Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy.Nat Biomed Eng2023https://conductscience.org/library/papers/36635419PubMed
735148751Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.Mol Cancer2022https://conductscience.org/library/papers/35148751PubMed
832206102Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs.Theranostics2020https://conductscience.org/library/papers/32206102PubMed
932624246The Roles of CD8+ T Cell Subsets in Antitumor Immunity.Trends Cell Biol2020https://conductscience.org/library/papers/32624246PubMed
1035588952Boosting extracellular vesicle secretion.Biotechnol Adv2022https://conductscience.org/library/papers/35588952PubMed
1137059065Metastasis.Cell2023https://conductscience.org/library/papers/37059065PubMed
1231088846Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically.Cancer Immunol Res2019https://conductscience.org/library/papers/31088846PubMed
1338769158Antibody-displaying extracellular vesicles for targeted cancer therapy.Nat Biomed Eng2024https://conductscience.org/library/papers/38769158PubMed
1439747604Measuring age-dependent viscoelasticity of organelles, cells and organisms with time-shared optical tweezer microrheology.Nat Nanotechnol2025https://conductscience.org/library/papers/39747604PubMed
1527009393Targeting metastasis.Nat Rev Cancer2016https://conductscience.org/library/papers/27009393PubMed
1639415091Screening of key genes related to M6A methylation in patients with heart failure.BMC Cardiovasc Disord2024https://conductscience.org/library/papers/39415091PubMed
1734555333Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.Lancet2021https://conductscience.org/library/papers/34555333PubMed
1838683997Genetic and phenotypic profiling of single living circulating tumor cells from patients with microfluidics.Proc Natl Acad Sci U S A2024https://conductscience.org/library/papers/38683997PubMed
1932736255An exosome-like programmable-bioactivating paclitaxel prodrug nanoplatform for enhanced breast cancer metastasis inhibition.Biomaterials2020https://conductscience.org/library/papers/32736255PubMed
2034910940Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox.Immunity2021https://conductscience.org/library/papers/34910940PubMed

See all 47 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
40879965Current perspectives and global trends of nanotechnology in advanced breast cancer: a bibliometric and visualized analysis.Discov Oncol2025https://conductscience.org/library/papers/40879965PubMed
40539389A Nano-Electro-Platform Enabling Evolutionary Screening and Remodeling of Tumor Cells for Metastasis Inhibition.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40539389PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40539389

GET https://conductscience.org/api/papers/v1/40539389/authors?page=2